Medicines planning
46 results
Applied filters
Preparing to use denosumab 120mg biosimilar
16 January 2026Biosimilars of denosumab 120mg (Xgeva) are available. We offer general information and implementation advice.
Annual medicines planning publication, Prescribing Outlook
12 January 2026Our annual output to support managed entry and budget planning for new medicines, new indications and patent expiries in the NHS.
Preparing to use ranibizumab biosimilar
5 November 2025Ranibizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team
The licence and supporting evidence for ranibizumab biosimilars
5 November 2025Four licensed ranibizumab biosimilars are available: Byooviz, Ongavia, Rimmyrah and Ximluci. Learn about the licensed indications and supporting evidence
Understanding biosimilar and generic market entry
12 September 2025New medicines have several protections against competition. Other factors influence availability of biosimilars or generics after loss of exclusivity.
Understanding biological and biosimilar medicines
1 August 2025Biosimilar medicines are a type of biological medicine that offer the NHS opportunities to deliver better value for certain conditions
Understanding data exclusivity and market protection
11 July 2025Data exclusivity and market protection periods prevent generic or biosimilar competition for at least 10 years after the originator medicine is licensed.
Understanding patents
11 July 2025Patents allow the inventor a finite period of monopoly in exchange for publicising the idea. We explain how they work with respect to medicines.
National Homecare Medicines Committee regional contacts
12 May 2025Contact details of the homecare regional specialists within the UK who sit on the National Homecare Medicines Committee (NHMC).
Good governance when implementing natalizumab biosimilar
11 December 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring and pharmacovigilance.